Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CODEPREX vs ALEVE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Cough suppression (FDA-approved)
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain,Fever
Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
4-6 hours (prolonged to 10-12 hours in hepatic impairment)
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Codeine undergoes O-demethylation via CYP2D6 to morphine; also N-demethylation to norcodeine via CYP3A4; homatropine is minimally metabolized.
Naproxen is extensively metabolized in the liver primarily via CYP2C9 to 6-O-desmethyl naproxen, and less than 5% is excreted unchanged in urine.
Renal: 60% as unchanged drug; Hepatic metabolism: 30% (inactive metabolites); Fecal: 10%
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
92% (primarily to albumin)
>99% bound to albumin; saturable at high concentrations.
1.5-2.0 L/kg (extensive tissue distribution)
0.16 L/kg; indicates distribution primarily in extracellular fluid.
Oral: 70-80% (first-pass metabolism reduces from 100% IV)
Oral: ~95%; immediate-release formulation.
Hydrocodone: GFR 30-80 m L/min: no adjustment; GFR 10-29 m L/min: reduce dose by 50% or extend interval to every 8-12 hours; GFR <10 m L/min: use with caution, consider alternative. Acetaminophen: GFR <10 m L/min: extend dosing interval to every 8 hours.
GFR 30-59 m L/min: reduce dose and avoid long-term use; GFR <30 m L/min: contraindicated.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and extend interval to every 8 hours; Class C: contraindicated due to acetaminophen toxicity risk and impaired hydrocodone metabolism.
Child-Pugh class A: no adjustment; Child-Pugh class B or C: avoid use.
Not recommended for pediatric use (no safety and efficacy data established).
2-12 years: 2.5-5 mg/kg/dose orally every 8-12 hours; maximum 10 mg/kg/day. 12 years and older: same as adult.
Start at low end of dosing range (1 tablet every 6 hours) due to increased sensitivity, reduced renal function, and risk of cognitive impairment.
Initiate at lowest effective dose (220 mg every 12 hours); maximum 440 mg per day; monitor renal function and GI bleeding risk.
Risk of respiratory depression, especially in children; contraindicated for postoperative pain management in children after tonsillectomy/adenoidectomy; contraindicated in children <12 years, and in children <18 years with risk factors for respiratory depression.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Naproxen is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
Respiratory depression; ultra-rapid metabolizers of CYP2D6 at risk of morphine toxicity; use in breastfeeding may cause infant opioid toxicity; anticholinergic effects of homatropine; risk of abuse and dependence; CNS depression with other depressants.
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure and edema,Renal toxicity,Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic toxicity (inhibition of platelet aggregation),Exacerbation of asthma,Hepatic effects,Pregnancy: avoid during third trimester
Hypersensitivity to codeine or homatropine; respiratory depression; acute or severe bronchial asthma; GI obstruction; paralytic ileus; children <12 years; children <18 years with tonsillectomy/adenoidectomy; use with MAOIs or within 14 days; breastfeeding women with CYP2D6 ultrarapid metabolism.
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in the setting of CABG surgery,Advanced renal disease,History of gastrointestinal bleeding or perforation related to previous NSAID therapy,Active gastrointestinal bleed
Grapefruit juice may inhibit CYP2D6 and reduce codeine conversion to morphine, potentially decreasing efficacy. High-fat meals may delay absorption of codeine. Avoid alcohol.
Avoid concurrent use of alcohol as it increases GI bleeding risk. No specific food restrictions; taking with food or milk may reduce dyspepsia. High potassium foods (e.g., bananas, spinach) may increase hyperkalemia risk in patients with renal impairment.
Based on available data, codeine is pregnancy category C. First trimester: Avoid due to possible association with congenital malformations (e.g., cardiovascular defects) from retrospective studies, though risk is low. Second and third trimesters: Risk of neonatal respiratory depression if used near term; chronic use may lead to neonatal withdrawal syndrome. Avoid if possible.
First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arteriosus premature closure risk begins. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, necrotizing enterocolitis, intracranial hemorrhage, and renal impairment; avoid after 30 weeks.
Codeine is excreted into breast milk. M/P ratio is approximately 2.5. Use with caution due to risk of infant CNS depression, especially in mothers who are CYP2D6 ultra-rapid metabolizers. AAP recommends lowest effective dose for shortest duration; monitor infant for drowsiness, difficulty breathing, or poor feeding.
Excreted in breast milk in low concentrations (M/P ratio ~0.12); relative infant dose <1% of maternal weight-adjusted dose. Compatible with breastfeeding; monitor infant for potential adverse effects (gastrointestinal upset, rash) at higher doses.
No standard dose adjustment required, but avoid use in third trimester due to risk of neonatal respiratory depression. If used, use lowest effective dose for shortest duration. Monitor for signs of maternal respiratory depression; consider reduced dose in patients with decreased respiratory reserve.
No specific pharmacokinetic-based dose adjustments; however, use lowest effective dose for shortest duration, especially after 20 weeks. Avoid use after 30 weeks gestation due to fetal risks. Increased volume of distribution may reduce serum concentrations but no dose adjustment recommended.
CODEPREX (codeine/guaifenesin) is a combination antitussive/expectorant. Codeine is a prodrug metabolized by CYP2D6 to morphine; ultra-rapid metabolizers risk toxicity. Avoid in children <18 years due to respiratory depression risk. Use with caution in patients with COPD or respiratory insufficiency. Constipation is common; consider prophylactic laxatives.
ALEVE (naproxen sodium) is a nonsteroidal anti-inflammatory drug (NSAID) with a longer half-life (12-17 hours) allowing twice-daily dosing. It carries a boxed warning for cardiovascular and gastrointestinal risk. Use lowest effective dose for shortest duration. Contraindicated in patients with aspirin allergy, perioperative pain in CABG surgery, and significant renal impairment. Monitor renal function in elderly, volume-depleted patients, and those on ACE inhibitors or diuretics.
Do not exceed recommended dose; may cause drowsiness, avoid driving or operating machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants as they increase sedation and respiratory depression risk.,Do not use in children under 18 years of age due to risk of serious breathing problems.,Contact your doctor if cough persists for more than 7 days or is accompanied by fever, rash, or persistent headache.,May cause constipation; increase fluid and fiber intake, and consider a stool softener if needed.,Store at room temperature away from moisture and heat.
Take with food or milk to reduce GI upset.,Do not exceed 2 tablets (440 mg) in 24 hours unless directed by a doctor.,Avoid alcohol consumption to lower risk of GI bleeding.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not use with other NSAIDs (e.g., ibuprofen, aspirin) unless prescribed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CODEPREX vs ALEVE, answered by our medical review team.
CODEPREX is a Antitussive Combination that works by Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.. ALEVE is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CODEPREX and ALEVE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CODEPREX is: Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.. The standard adult dose of ALEVE is: 220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CODEPREX and ALEVE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CODEPREX is classified as Category C. Based on available data, codeine is pregnancy category C. First trimester: Avoid due to possible association with congenital malformations (e.g., cardiovascular defects) from retro. ALEVE is classified as Category C. First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arter. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.